Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

67.82USD
4:00pm EDT
Change (% chg)

$0.80 (+1.19%)
Prev Close
$67.02
Open
$66.85
Day's High
$67.96
Day's Low
$66.59
Volume
386,642
Avg. Vol
578,810
52-wk High
$120.87
52-wk Low
$60.22

Select another date:

Fri, Jun 1 2018

Photo

FDA approves lower dose of Lilly-Incyte arthritis drug

The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.

FDA approves lower dose of Lilly-Incyte arthritis drug

June 1 The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.

BRIEF-Incyte Reports Q1 Loss Of $0.19 Per Share

* INCYTE REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS

FDA panel against higher dose of Lilly-Incyte arthritis drug

An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration

* IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER

UPDATE 2-FDA panel against higher dose of Lilly-Incyte arthritis drug

* Approval in only 2 mg dose limits commercial potential- analysts

FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug

April 23 A U.S. FDA advisory committee voted 10-to-5 on Monday against approving a higher dose of a rheumatoid arthritis drug developed by Eli Lilly & Co and Incyte Corp, but recommended that it be approved in a lower dose.

UPDATE 2-Incyte tumbles after combo therapy with Merck fails study

April 6 Incyte Corp's shares sank more than 20 percent on Friday after its experimental cancer drug failed to bolster the effectiveness of Merck & Co's blockbuster Keytruda to treat skin cancer patients.

Incyte, Merck melanoma combo therapy fails study, shares slide

Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co's Keytruda failed to meet the main goal in a late-stage study.

Incyte's combo therapy for skin cancer fails in late-stage study

April 6 Incyte Corp said on Friday an independent committee concluded that its drug in combination with Merck & Co's Keytruda for a type of skin cancer failed to meet the main goal in a late-stage study.

Select another date: